Article by Yippee-Ki-Yay

Accelerant Holdings: is there a treasure hidden behind the loss?

Buy signal | Free publication | 13 Jul 2026

Accelerant Holdings (ARX): is this insurance gem, which is flying high on the stock market, worth your money?

1. Who are Accelerant Holdings?

Forget the outdated image of traditional insurance. Accelerant Holdings, which has been listed since its IPO in 2025, has established itself as a specialised insurance exchange (specialty insurance exchange). In practical terms, the company connects expert underwriters (known as ‘Members’, who are MGAs highly specialised in complex niche risks) with reinsurance capital providers. It does not bear all the risk itself: it orchestrates the ecosystem, earns commissions and underwriting income, and scales up without needing the balance sheet of a giant traditional insurer. Translated with DeepL.com (free version)

The result: dizzying growth. Turnover has risen from $100.6 million in 2021 to $873.5 million in 2025. That’s an 8.7-fold increase in four years. The sort of trajectory that makes growth investors’ eyes light up, but which also requires a thorough scrutiny of the figures before pulling out the credit card.

2. Detailed Financial Analysis (marked out of 5)

📈 Turnover: 5/5

Almost vertical growth: +49.7% between 2024 (583.6 M) and 2025 (873.5 M) and 2025 (873.5 M) and 2025 (873.5 M), following similar surges in previous years. The forecasts confirm this momentum, with $1.10 billion expected in 2026 and $1.24 billion in 2027. That’s a massive figure, and it shows no signs of slowing down.

💰 Net score: 2/5

That’s a bit of a blow. The company posted a net loss of -$1,354.1 million in 2025, compared with a profit of $27.2 million in 2024. Before you panic: this loss is mainly due to an exceptional charge of $1,379.7 million (“Unusual Expense”), most likely linked to non-cash accounting items relating to the initial public offering (share-based payments, conversion of instruments). Excluding this item, the underlying operating performance remains broadly in balance. The market is well aware of this, incidentally, as forecasts predict a return to a net profit of $160 million as early as 2026. But until this is confirmed in black and white, caution is warranted.

🏦 Debt: 4.5/5

Frankly, there’s nothing to criticise here. A ridiculously low total debt of $121.3 million against cash and cash equivalents of $1,799.3 million. The balance sheet is virtually debt-free. ‘Policy liabilities’ (traditional insurance liabilities) inflate the balance sheet total but do not constitute financial debt in the strict sense. A very sound structure.

📊 ROE (return on equity): 4/5

The historical ROE is weighed down by past losses, but the forecasts speak for themselves: 23.7 per cent in 2026, 28.8 per cent in 2027, rising to 33.7 per cent in 2028. If these trends are confirmed, we are looking at levels of profitability on a par with the best specialist insurance companies on the market.

🎯 Market performance / Valuation: 3.5/5

With a price-to-sales ratio of 3.18x based on 2025 sales and a forward P/E ratio for 2026 of around 16.7x ($12.44 / forecast EPS of $0.743), the valuation is neither a bargain nor exorbitant. The consensus among analysts clearly leans towards ‘Buy’. Fair enough, though it’s not exactly a bargain either.

🏆 Overall average rating: 3.8/5

A rapidly growing company that is financially very sound on the balance sheet, but whose reported profitability has yet to prove its consistency once the ‘noise’ surrounding the IPO has subsided.

3. Outlook & Forecasts (2026–2027)

The consensus forecasts are robust: revenue is expected to reach $1.10 billion in 2026 and then $1.24 billion in 2027, with EBITDA rising from $284 million to $351 million over the same period. EPS follows suit: from $0.743 to $0.928.

Price estimate: applying a stable valuation multiple (P/S ~3.2x or P/E ~17–18x, consistent with the current growth profile), this yields a range of $15 to $17 by the end of 2026, and $18 to $21 by the end of 2027. This is not a sure-fire strategy, just a projection based on the current momentum continuing — and the market loves to reward companies that deliver double-digit growth with profitability that improves quarter on quarter.

4. Sector Analysis (Speciality Insurance / Insurtech)

Key strengths of the sector:

  • The “speciality insurance” market is experiencing strong structural growth, driven by increasingly complex risks (cyber, climate, liability)
  • A platform-based “asset-light” model, requiring less capital than a traditional insurer
  • Strong barriers to entry (underwriting expertise, member network)
  • A hardening cycle in the insurance market that favours specialist players

Weaknesses in the sector:

  • High sensitivity to interest rate cycles and capital markets (reinsurance)
  • Risk of catastrophic claims (climate, cyber) that is difficult to model
  • Growing competition from traditional giants who are digitising their offerings
  • Heavy and evolving regulatory framework depending on the jurisdiction

5. Conclusion: should you buy it?

Accelerant Holdings ticks a great many boxes: explosive revenue growth, a virtually debt-free balance sheet, abundant cash, and ROE forecasts that are cause for optimism. The net loss for 2025 looks alarming at first glance, but it is largely attributable to a one-off item linked to the IPO rather than a genuine operational problem.

My honest opinion: this is a ‘growth’ stock to watch very closely and to build up a position in gradually, rather than buying blindly in one go. The potential is real — but caution regarding the quality of the net profit remains warranted until 2026 confirms in black and white a return to clear profitability. Verdict: build up a position gradually, don’t go all-in.

  • Signal : Buy
  • Budget/Investment : Low/Medium
  • Reinforcement required : Ye, under $10
  • Exposure : Medium
  • Horizon : 1 to 3 years
  • Potential profitability : +44% to +68%
  • Ref. ISIN code : KYG008941083